Debu Tripathy on Hormone Therapy Compliance in Patients with Breast Cancer

Video

Debu Tripathy discuss how to encouragecompliance and adherence for patients with breast cancer who are receiving hormone therapy.

Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, discusses how nurses can encourage compliance and adherence for patients with breast cancer.

There are many reasons for patient non-adherence to hormone therapy; it is not just because of side effect burden. Tripathy suggests careful counseling from nurses so that patients can get a full understanding of the treatment. Using a full team approach to care with active communication is key.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Photo of the arm of a person with lymphedema

Oncology Nurses Aid BC Survivorship and Lymphedema Prevention

Erin Dickman, DNP, RN, OCN
June 17th 2025
Article

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Anatomical graphic of a person with a breast tumor

PROs Higher For Imlunestrant With/Without Abemaciclib in ER+, HER2– BC

Tim Cortese
June 3rd 2025
Article

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Illustration of two people in lab coats using scientific instruments with a breast icon in the background

Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer

Caroline Seymour
June 2nd 2025
Article

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

Line illustration of a breast

Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

Kristi Rosa
May 31st 2025
Article

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.